Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;241(7):e70073.
doi: 10.1111/apha.70073.

Cardiolipin Remodeling in Cardiovascular Diseases: Implication for Mitochondrial Dysfunction

Huijie Zhang  1 , Fengzhi Yu  1 , Zhenjun Tian  2 , Dandan Jia  1
Affiliations
Review

Cardiolipin Remodeling in Cardiovascular Diseases: Implication for Mitochondrial Dysfunction

Huijie Zhang et al. Acta Physiol (Oxf). 2025 Jul.

Abstract

Aim: Mitochondrial dysfunction is pivotal in both the development and progression of cardiovascular diseases (CVDs), though its exact mechanisms remain unclear. Cardiolipin (CL), a key mitochondrial phospholipid, is involved in various mitochondrial functions, including dynamics, membrane integrity, oxidative phosphorylation, mitochondrial DNA maintenance, and mitophagy. Due to enzyme limitations in the CL biosynthesis pathway, premature CL undergoes remodeling to acquire the proper acyl content for its function. Disruption in CL composition leads to mitochondrial dysfunction, contributing significantly to CVDs. The purpose of this review is to explore the role of CL remodeling in the mechanism of mitochondrial dysfunction that occurs in CVDs.

Methods: This review examines CL's critical role in mitochondrial function, the consequences of CL deficiencies in CVDs, and the impact of mutations or deficiencies in CL remodeling enzymes-tafazzin (TAZ), Acyl-CoA:lysocardiolipin acyltransferase-1 (ALCAT1), and Monolysocardiolipin acyltransferase (MLCLAT1)-on CL homeostasis, mitochondrial function, and CVDs pathogenesis. Emerging CL-targeted therapies are also reviewed.

Results: Proper CL function is crucial for mitochondrial health and cardioprotection. Pathological CL remodeling due to mutations or deficiencies in TAZ, ALCAT1, or MLCLAT1, drives mitochondrial dysfunction and accelerates CVDs progression. Based on these insights, current CL-based therapeutic strategies are also summarized, including precision medicine/gene therapy, targeted pharmacotherapy, and dietary interventions.

Conclusion: Targeting CL may represent a promising clinical therapeutic strategy for CVDs.

Keywords: ALCAT1; cardiolipin remodeling; cardiovascular diseases; mitochondrial dysfunction; tafazzin.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. N. J. Kassebaum, M. Arora, R. M. Barber, et al., “Global, Regional, and National Disability‐Adjusted Life‐Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE), 1990–2015: A Systematic Analysis for the Global Burden of Disease Study 2015,” Lancet 388, no. 10053 (2016): 1603–1658.
    1. A. R. Omran, “The Epidemiologic Transition. A Theory of the Epidemiology of Population Change,” Milbank Memorial Fund Quarterly 49, no. 4 (1971): 509–538.
    1. H. Zhang, Y. Zhang, J. Zhang, and D. Jia, “Exercise Alleviates Cardiovascular Diseases by Improving Mitochondrial Homeostasis,” Journal of the American Heart Association 13, no. 19 (2024): e036555.
    1. D. Jia, Z. Tian, and R. Wang, “Exercise Mitigates Age‐Related Metabolic Diseases by Improving Mitochondrial Dysfunction,” Ageing Research Reviews 91 (2023): 102087.
    1. B. Kornmann and P. Walter, “ERMES‐Mediated ER‐Mitochondria Contacts: Molecular Hubs for the Regulation of Mitochondrial Biology,” Journal of Cell Science 123, no. Pt 9 (2010): 1389–1393.

LinkOut - more resources